Introduction {#Sec1}
============

Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, was estimated to affect 33.5 million people worldwide in 2010, with a notable increase in incidence and prevalence in comparison with previous decades \[[@CR1]\]. In the next 50 years, the prevalence of AF, which increases with age, is expected to double \[[@CR2], [@CR3]\], which may be of concern in rapidly developing countries such as Brazil, China, India, and Indonesia \[[@CR1], [@CR4]\].

AF is an established risk factor for a first or recurrent stroke \[[@CR5]\]. The risk of stroke among patients with AF has been estimated between 1 and 20% per year \[[@CR6], [@CR7]\]. Despite the efficacy of warfarin in preventing a first or recurrent stroke among patients with AF \[[@CR8]\], and notwithstanding the recommendation for stroke prophylaxis in selected individuals with AF \[[@CR6], [@CR9]\], there is evidence of underuse of anticoagulants in such patients \[[@CR10], [@CR11]\]. Additionally, underuse of warfarin among patients with AF at moderate or high risk for stroke has been reported in various countries \[[@CR12], [@CR13]\]. It is conceivable that underuse of warfarin when indicated is, in part, due to the concerns about its safety profile and need for close monitoring of the international normalized ratio (INR).

Large randomized trials have shown that direct thrombin and factor Xa inhibitors are either non-inferior or superior to warfarin in terms of efficacy, with a decreased risk of severe bleeding, among patients with AF and moderate to high risk of stroke. The use of agents from these classes---also known as non-vitamin K antagonist oral anticoagulants (NOACs)---allows for fixed dosing and does not require laboratory monitoring. The rapid onset and relatively short half-life of anticoagulant action offers advantages for NOACs over warfarin in some clinical settings. It is expected that the use of such agents will progressively replace warfarin in the future. This review summarizes the published literature with an emphasis on the expected absolute benefits from the introduction of such agents. This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.

Summary of Results with New Oral Anticoagulants {#Sec2}
===============================================

Direct Comparisons Between Warfarin and New Oral Anticoagulants {#Sec3}
---------------------------------------------------------------

NOACs include direct thrombin inhibitors (e.g., dabigatran) and factor Xa inhibitors (e.g., rivaroxaban, apixaban, and edoxaban). To date, a direct comparison of commercially available NOACs in a prospective head-to-head trial has not been performed. In a systematic review of 12 randomized trials, each comparing one of these NOACs against warfarin, the pooled relative risk (RR) of death from any cause was 0.89 \[95% confidence interval (CI) 0.83--0.96\], thus indicating a significant reduction of all-cause mortality of 11% in favor of NOACs. Likewise, significant benefits were demonstrated for NOACs in terms of stroke or systemic embolism (RR 0.77, 95% CI 0.70--0.86), as well as major bleeding (RR 0.86, 95% CI 0.80--0.93). Conversely, no statistically significant benefit was found for the pooled risk of ischemic stroke, for which separate data were available from 11 trials (RR 0.92, 95% CI 0.081--1.04) \[[@CR14]\]. These pooled relative results include data from eight randomized phase 2 trials and four phase 3 trials, although none of these trials studied edoxaban. In the following paragraphs, the individual results of phase 3 trials of dabigatran, rivaroxaban, apixaban, and edoxaban are briefly discussed in chronological publication order.

In the RE-LY^®^ (Randomized Evaluation of Long-term anticoagulation therapY) trial, a pivotal, open-label, phase 3 trial, two doses of dabigatran (150 and 110 mg, both twice daily) were compared with warfarin (adjusted to achieve a target INR of 2.0--3.0) in 18,113 patients with AF plus at least one additional risk factor for stroke \[[@CR15], [@CR16]\]. All comparisons were made according to the intention-to-treat principle, and the participants were randomly assigned to receive one of the two doses of dabigatran with no prior selection. The dose of dabigatran currently approved by the US Food and Drug Administration (FDA; 150 mg twice daily) was found to be superior to warfarin in reducing stroke or systemic embolism (RR 0.65, 95% CI 0.52--0.81, *p* \< 0.001), which was the primary trial end point. At a lower dose (110 mg twice daily) dabigatran was non-inferior to warfarin, thus also achieving the protocol-specified primary objective (RR 0.90, 95% CI 0.74--1.10, *p* = 0.30). Dabigatran at 150 mg twice daily was superior to warfarin for both ischemic (RR 0.76, 95% CI 0.59--0.98, *p* = 0.0351) and hemorrhagic (RR 0.26, 95% CI 0.14--0.49, *p* \< 0.001) strokes, whereas at 110 mg twice daily it was non-inferior to warfarin for ischemic stroke and superior for hemorrhagic stroke (RR 0.31, 95% CI 0.17--0.56, *p* \< 0.001). There was no significant reduction in mortality from the use of dabigatran (*p* = 0.051 for 150 mg twice daily and *p* = 0.13 for 110 mg twice daily), but the rate of the composite of major vascular events, major bleeding, or death (i.e., net clinical benefit) was significantly reduced by the 150 mg twice-daily dose (*p* = 0.02). The rate of major bleeding was lower with dabigatran 110 mg twice daily (RR 0.80, 95% CI 0.70--0.93, *p* = 0.003), but similar for dabigatran 150 mg twice daily (*p* = 0.31), in comparison with warfarin. The rates of intracranial hemorrhage and fatal bleeding with both doses of dabigatran were also lower. The rates of major gastrointestinal bleeding were significantly higher with the dabigatran 150 mg twice-daily dose when compared with warfarin (RR 1.50, 95% CI 1.19--1.89, *p* \< 0.001). Selected results of this study and others are summarized in Table [1](#Tab1){ref-type="table"}. In subgroup analyses of patients with previous stroke or transient ischemic attack, RR reductions were consistent with those observed in the overall study population---albeit with no statistical significance, possibly as a result of insufficient power in subgroups \[[@CR17]\]. Dyspepsia was the only adverse event that was significantly more common with dabigatran than with warfarin \[[@CR15]\].Table 1Selected patient features and results from pivotal phase 3 trials of four new anticoagulants \[[@CR15], [@CR18]--[@CR20]\]Features and resultsDabigatran\
110 mg^a^Dabigatran\
150 mg^a^Rivaroxaban\
20 mgApixaban\
5 mg^a^Edoxaban\
30 mgEdoxaban\
60 mgPatients, *N*601560767131912070347035Age, years71.4^b^71.5^b^73^c^70^c^72^c^72^c^CHADS~2~ score, mean2.12.23.52.12.82.8Median follow-up, years2^d^2^d^1.91.82.8^d^2.8^d^TTR (%), mean646455626565Primary end pointNISuperiorNISuperiorNINIIschemic strokeNISuperiorNINIInferiorNIHemorrhagic strokeSuperiorSuperiorSuperiorSuperiorSuperiorSuperiorIntracranial bleedingSuperiorSuperiorSuperiorSuperiorSuperiorSuperiorAny bleedingSuperiorSuperiorNISuperiorSuperiorSuperiorResults refer to doses compared head-to-head with warfarin in each trial. All trials had stroke or systemic embolism as a primary end point*CHADS*~*2*~ Congestive heart failure, Hypertension, Age (\> 65 = 1 point, \> 75 = 2 points), Diabetes, and Stroke/TIA (2 points), *NI* noninferior, *TTR* time in therapeutic range (for warfarin arms of corresponding trial)^a^Twice-daily doses; for apixaban, the criteria for a 2.5 mg twice-daily dose is discussed earlier in the results section^b^Mean^c^Median^d^Reported in aggregate for all trial arms

Rivaroxaban was compared with warfarin in two phase 3 trials. The larger ROCKET AF (Rivaroxaban Versus Warfarin in Nonvalvular AF) trial was a double-blind, non-inferiority study in 14,264 patients with AF at moderate to high risk of stroke \[[@CR18]\]. The primary end point was the composite of stroke or systemic embolism. Although rivaroxaban (20 mg per day) was found to be non-inferior to warfarin (target INR 2.0--3.0) in the per-protocol analysis of the primary end point \[hazard ratio (HR) 0.79, 95% CI 0.66--0.96, *p* \< 0.001 for non-inferiority\], the intention-to-treat analysis could not confirm the superiority of rivaroxaban (HR 0.88, 95% CI 0.74--1.03, *p* \< 0.001 for non-inferiority and *p* = 0.12 for superiority). There was no significant difference between the arms in the rate of major and non-major clinically relevant bleeding, a major composite safety end point (RR 1.03, 95% CI 0.96--1.11, *p* = 0.44), but there were lower rates of intracranial hemorrhage (*p* = 0.02) and fatal bleeding (*p* = 0.003) with rivaroxaban. Gastrointestinal bleeding was more common with rivaroxaban versus warfarin (3.2 vs. 2.2%, *p* \< 0.001). Selected results of this trial and others are presented in Table [1](#Tab1){ref-type="table"}. There was a trend toward an interaction between the primary end point and a history of prior stroke, transient ischemic attack, or systemic embolism (*p* = 0.072), and a significant interaction between the primary end point and safety (*p* = 0.039). Among subjects without a history of stroke, transient ischemic attack, or systemic embolism, rivaroxaban was significantly superior to warfarin in achieving the primary efficacy (HR 0.71, 95% CI 0.54--0.94) and safety (HR 0.59, 95% CI 0.42--0.83) end points. Conversely, there was no difference between the primary efficacy (HR 0.98, 95% CI 0.8--1.2) or safety (HR 0.91, 95% CI 0.72--1.14) of rivaroxaban and warfarin in the subgroup with a history of prior stroke, transient ischemic attack, or systemic embolism.

Apixaban was compared with warfarin (target INR 2.0--3.0) in the double-blind ARISTOTLE (Apixaban for Reduction In STroke and Other ThromboemboLic Events in AF) trial, which enrolled 18,201 patients with AF plus at least one additional risk factor for stroke \[[@CR19]\]. The apixaban dose was 5 mg twice daily, unless patients met two or more of the criteria for a 2.5 mg twice-daily dose (age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dl). Apixaban was superior to warfarin for the primary end point (stroke or systemic embolism; HR 0.79, 95% CI 0.66--0.95). The relative risk reduction was greater for hemorrhagic (49%) than for ischemic or uncertain types of stroke (8%, not statistically significant; HR 0.92, 95% CI 0.74--1.13, *p* = 0.42). The secondary end points of death (HR 0.89, 95% CI 0.80--0.99, *p* = 0.047) and major bleeding (HR 0.69, 95% CI 0.60--0.80, *p* \< 0.001) favored apixaban. The rates of gastrointestinal bleeding were similar in the apixaban and warfarin groups (HR 0.89, 95% CI 0.70--1.15, *p* = 0.37). Selected results of this trial are also displayed in Table [1](#Tab1){ref-type="table"}. Although the results of subgroup analyses were generally consistent with treatment effects seen for the overall study population, significant interactions suggested greater reduction in bleeding with apixaban among those without diabetes mellitus and moderate or severe renal impairment.

Finally, edoxaban was assessed in ENGAGE AF-TIMI 48 (Effective aNticoaGulation with factor xA next GEneration in AF---Thrombolysis In Myocardial Infarction study 48), a double-blind trial \[[@CR20]\]. In this trial, 21,105 patients with AF and moderate or high risk of stroke were randomized to receive two once-daily regimens of edoxaban (60 or 30 mg) or warfarin (target INR 2.0--3.0). The primary efficacy end point was stroke or systemic embolism, whereas the principal safety end point was major bleeding. Primary comparisons in a modified intention-to-treat population favored both the 60-mg dose (HR 0.79, 97.5% CI 0.63--0.99, *p* \< 0.001 for non-inferiority) and the 30-mg dose of edoxaban (HR 1.07, 97.5% CI 0.87--1.31, *p* = 0.005 for non-inferiority). A prespecified superiority analysis using the intention-to-treat population showed trends in favor of the 60-mg dose of edoxaban versus warfarin (HR 0.87, 95% CI 0.73--1.04, *p* = 0.08) and against the 30-mg dose of edoxaban versus warfarin (*p* = 0.10). Other end points that favored edoxaban significantly were the rate of major bleeding (HR 0.80, 95% CI 0.71--0.91 for the 60-mg dose and HR 0.47, 95% CI 0.41--0.55 for the 30-mg dose) and the rates of death from cardiovascular causes (HR 0.86, 95% CI 0.77--0.97 for the 60-mg dose and HR 0.85, 95% CI 0.76--0.96 for the 30-mg dose). The rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) favored only the 60-mg dose of edoxaban (HR 0.87, 95% CI 0.78--0.96). Gastrointestinal bleeding was significantly more frequent with the 60-mg dose of edoxaban than with warfarin. Selected results of this trial are presented in Table [1](#Tab1){ref-type="table"}. A prespecified analysis of stroke rates indicated that patients receiving 60 mg of edoxaban showed significantly lower stroke rates (HR 0.8, 95% CI 0.65--0.98), whereas patients receiving 30 mg of edoxaban showed similar stroke rates (HR 1.10, 95% CI 0.91--1.32) compared with warfarin \[[@CR21]\]. However, both doses of edoxaban were significantly more effective than warfarin in reducing the rates of hemorrhagic stroke and other types of intracranial bleeding \[[@CR20]\].

In summary, compared with warfarin, the four NOACs discussed above significantly reduce the risk of hemorrhagic stroke (Table [1](#Tab1){ref-type="table"}). Only dabigatran (at the dose of 150 mg twice daily) was found to significantly reduce the risk of ischemic stroke. More recently, a meta-analysis included the four larger pivotal trials discussed above (RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48) \[[@CR22]\]. NOACs were found to significantly reduce the risks of stroke or systemic embolism (RR 0.81, 95% CI 0.73--0.91), all-cause mortality (RR 0.90, 95% CI 0.85--0.95), and intracranial hemorrhage (RR 0.48, 95% CI 0.39--0.59). The benefit regarding strokes was mainly driven by a reduction in hemorrhagic stroke (RR 0.49, 95% CI 0.38--0.64). Conversely, NOACs significantly increased the risk of gastrointestinal bleeding (RR 1.25, 95% CI 1.01--1.55).

Indirect Comparisons Among New Oral Anticoagulants {#Sec4}
--------------------------------------------------

Given the availability of at least four NOACs, each with a different efficacy and safety performance versus warfarin, the question arises as to whether any of these agents is preferable to others, especially considering that individual randomized trials disclosed nuances whose practical value remain uncertain, especially with regard to non-composite end points (e.g., the rate of ischemic stroke alone) and to subgroups with a preferential benefit (e.g., patients in primary or secondary prevention of stroke or transient ischemic attack). Unfortunately, there are no published data with direct comparisons between NOACs.

An adjusted indirect comparison of apixaban, dabigatran (150 mg twice daily), and rivaroxaban using data from four randomized trials on one of these agents versus warfarin \[[@CR15], [@CR18], [@CR19], [@CR23]\] suggested that dabigatran decreases the risks of stroke or systemic embolism, as well as ischemic and hemorrhagic strokes versus rivaroxaban, with no differences in mortality. Furthermore, the study suggested that apixaban decreases the risk of major and gastrointestinal bleedings versus dabigatran and major bleeding versus rivaroxaban, but increases the risk of systemic embolism versus rivaroxaban \[[@CR24]\]. Another indirect meta-analysis comparing the outcomes of the three pivotal trials for apixaban, dabigatran, and rivaroxaban \[[@CR15], [@CR18], [@CR19]\] drew very similar conclusions \[[@CR25]\]. The same authors of the previous study assessed the results separately in primary and secondary prevention and found that, for patients with prior stroke, apixaban, dabigatran, and rivaroxaban had essentially similar efficacy for the main outcomes; however, hemorrhagic stroke, vascular death, major bleeding, and intracranial bleeding were less common with twice-daily dabigatran 110 mg than with rivaroxaban. For patients with no prior stroke, all three drugs showed few differences. Apixaban was superior to twice-daily dabigatran 110 mg for disabling or fatal stroke, but inferior to twice-daily dabigatran 150 mg for stroke; however, apixaban was superior to twice-daily dabigatran 150 mg for bleeding. No significant differences were observed for the efficacy and safety end points between twice-daily dabigatran 150 mg and rivaroxaban. Finally, no significant differences were found in efficacy end points between apixaban and rivaroxaban, but the former led to less major bleeding \[[@CR26]\]. Ideally, all these hypothesis-generating results should be confirmed in randomized trials directly comparing the NOACs of interest.

Where the NOACs have been evaluated in postmarketing studies in routine clinical practice, the real-world data generally support the efficacy and safety profiles observed in their respective pivotal randomized trials \[[@CR27]--[@CR29]\].

One of the largest independent real-world studies was conducted by the US FDA with an analysis of the Medicare database \[[@CR27]\], which included over 134,000 Medicare beneficiaries, all aged ≥ 65 years, with 37,587 person-years of follow-up. The study showed that dabigatran was associated with reduced risks of ischemic stroke, intracranial hemorrhage, and death, and an increased risk of gastrointestinal hemorrhage, when compared with warfarin in elderly patients with non-valvular AF. Overall, the independent results of the US FDA Medicare study are consistent with the results of the pivotal RE-LY trial, indicating that dabigatran has a favorable risk profile, thus leading to no changes to the current recommendations for its use. A nationwide cohort study in Denmark (*N* = 61,678) assessed safety and efficacy of apixaban, dabigatran, rivaroxaban, and warfarin. No significant differences were observed in the rates of stroke between NOACs and the warfarin groups. However, the rates of major bleeding and mortality were significantly lower in the dabigatran and apixaban groups compared with the warfarin group \[[@CR28]\]. A retrospective cohort study analyzed the safety data of NOACs and warfarin in patients (*N* = 44,057) with nonvalvular AF from a US administrative claims database. The rates of risk of major bleeding were consistent with the findings from pivotal randomized trials that compared NOACs with warfarin \[[@CR29]\]. These real-world studies are important to support understanding of the real drug safety profiles of approved medicines in routine clinical practice.

Absolute Measures of Efficacy {#Sec5}
-----------------------------

Measures of relative benefits from medical interventions, such as RRs, odds ratios, and HRs, do not immediately provide the estimated benefit to be derived by an individual patient, something best done by considering the expected absolute benefit. This can be computed by considering the patient's estimated baseline risk of an outcome of interest (in the absence of intervention) and the relative benefit derived from clinical trials or meta-analyses. The absolute risk reduction (ARR) is the difference in the rates of the outcome of interest in the presence and in the absence of the intervention in clinical trials or meta-analyses. The number needed to treat (NNT) is the number of patients who must be treated in order to prevent one case of the outcome of interest, thus representing the expected absolute benefit \[[@CR30]\]. Mathematically, the NNT is the reciprocal of the ARR (NNT = 1/ARR). An absolute measure of harm \[the number needed to harm (NNH)\] may be computed in the same way as the NNT if the ARR is replaced by the absolute risk increase. Thus, the NNH is the reciprocal of the absolute risk increase. The computation of the NNT and the NNH only makes sense when there are statistically significant advantages (i.e., superiority) or disadvantages (i.e., inferiority), respectively, for the use of intervention regarding outcomes of interest in comparison with no use of the intervention (i.e., control).

Considering the pooled results of the meta-analysis discussed previously, the NNT to prevent one death from the use of an NOAC instead of warfarin is 244, and the corresponding NNT for cardiovascular mortality is 500. NNTs are more favorable for the outcomes of stroke or systemic embolism (137) and major bleeding (157). For the latter, there was significant heterogeneity in a random-effects model. A subgroup analysis examining each NOAC separately showed that dabigatran and apixaban led to significant reductions in the rate of major bleeding, whereas rivaroxaban and edoxaban did not \[[@CR14]\]. No NNHs were computed in this meta-analysis. Table [2](#Tab2){ref-type="table"} displays selected NNTs and NNHs based on the individual analysis of each pivotal study of these four agents, with the caveat that such metrics cannot be computed for agents that have not proven a statistically significant difference against warfarin in selected outcomes. For the sake of comparison, the NNT for the use of aspirin as primary prevention of non-fatal myocardial infarctions has been estimated at 200 \[[@CR31]\].Table 2Selected absolute measures from pivotal phase 3 trials of four new anticoagulants (yearly NNT or NNH in head-to-head comparisons with warfarin within each trial) \[[@CR15], [@CR18]--[@CR20]\]Features and resultsDabigatran\
110 mg^a^Dabigatran\
150 mg^a^Rivaroxaban\
20 mgApixaban\
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30 mgEdoxaban\
60 mgPrimary end pointN/A167^b^N/A303^b^N/AN/AIschemic strokeN/A175^b^N/AN/A192^c^N/AHemorrhagic stroke385^b^357^b^333^b^434^b^323^b^476^b^Intracranial bleeding189^b^227^b^250^b^213^b^169^b^217^b^Gastrointestinal bleedingN/A204^c^100^c^N/A244^b^357^c^N/A refers to situations where neither superiority nor inferiority was demonstrated, thus precluding computation of NNTs and NNHs*NNH* numbers needed to harm, *NNT* numbers needed to treat^a^Twice-daily doses; for apixaban, see the text for the explanation regarding the criteria for the 2.5-mg dose^b^NNT^c^NNH

Applying NNT to a Country {#Sec6}
-------------------------

The economic factors that are not considered in this review but discussed elsewhere \[[@CR6]\] must also be taken into account, especially in developing countries, where warfarin may continue to have a role in selected patients \[[@CR32]\]. A simple exercise using Brazilian data, for example, may illustrate this point. The population of Brazil is approximately 200 million, with nearly 10% of the population aged ≥ 60 years \[[@CR33]\]. A population-based study of residents aged ≥ 65 years living in an economically deprived area of São Paulo determined the prevalence of AF at 2.4% \[[@CR34]\]. Based on this information, we estimate that 480,000 individuals in Brazil have AF. Considering that nearly 75% of these individuals would have an indication to receive anticoagulation \[[@CR12]\], 360,000 users of warfarin potentially exist. The NNT for NOACs with proven superiority to warfarin may be used to compute the annual number of strokes that could be prevented. If dabigatran (150 mg twice daily) and apixaban were used instead of warfarin in Brazil, they could prevent 2156 and 1188 strokes, respectively, every year \[[@CR15], [@CR16], [@CR19]\]. These rough estimates ignore the burden of AF in people younger than 60 years of age, the different prevalence of AF between males and females \[[@CR2]\], the potentially different effect of individual agents on patients at moderate and at high risk, and the percentage of individuals with moderate and high risk for stroke who should receive anticoagulants according to guidelines.

Limitations {#Sec7}
-----------

The main limitation of this review is that, in the absence of head-to-head trials, all the data are hypothesis generating. In addition, it should be noted that the use of the NNT is not without drawbacks or controversy \[[@CR35], [@CR36]\]. Two problems with the NNT are immediately apparent in the analysis of the four phase 3 trials of the currently available NOACs \[[@CR15], [@CR18]--[@CR20]\]. The first problem relates to the slightly different patient populations investigated in each trial; in that regard, the direct comparison of NNTs may be misleading because this absolute measure clearly reflects the baseline risk of patients, which was different across studies. For example, the mean CHADS~2~ score \[Congestive heart failure, Hypertension, Age (\> 65 = 1 point, \> 75 = 2 points), Diabetes, and Stroke/TIA: a prediction for estimating the risk of strokes\] was higher in ROCKET AF (3.5) and ENGAGE AF-TIMI 48 (2.8) than in RE-LY (2.1 for the lower dose and 2.2 for the higher dose) and ARISTOTLE (2.1). Likewise, the percentage of patients with a previous stroke or transient ischemic attack (and, in some cases, systemic embolism) was higher in ROCKET AF (55%) and ENGAGE AF-TIMI 48 (28%) than in RE-LY (20%) and ARISTOTLE (19%). Patients with a higher baseline risk derive more absolute benefit from an intervention with a given relative impact than patients with a lower baseline risk undergoing the same intervention. The second problem relates to different results in the control arm across the trials. Notably, the quality of anticoagulation, as indicated by the mean percentage of time the INR remained in the therapeutic range, was higher in ENGAGE AF-TIMI 48 (65%) and in RE-LY (64%) than in ARISTOTLE (62%) and in ROCKET AF (55%). Since the NNT is a function of the difference between the rates of the outcomes of interest with NOACs and with warfarin, differing results in control arms influence the computed NNTs.

Conclusions {#Sec8}
===========

Encouraging progress has been achieved with the introduction of NOACs that, overall, have displayed a superior efficacy and improved safety in comparison with warfarin \[[@CR15], [@CR18]--[@CR20]\]. As noted earlier, differences exist in the efficacy and safety profile among the four currently available NOACs. Careful analysis of trial results so far indicates that the choice among the available agents is not easy. Despite the limitations of the NNT, this may be a valid metric to be considered by a clinician faced with four different agents to be used instead of warfarin in patients with AF plus moderate or high stroke risk. In addition, economic as well as health factors should be considered, as they play a major role. In the example of applying NNT to Brazilian data, around 2156 and 1188 stroke events could be prevented per year by using dabigatran or apixaban, respectively, instead of warfarin \[[@CR6], [@CR32]\].

Regardless of these limitations, the number of patients with AF in whom a stroke could be prevented by the use of NOACs instead of warfarin would only increase, accompanying the expected increase in prevalence of AF in Brazil and elsewhere. It is hoped that future studies on the efficacy, safety, and economic performance of NOACs will further allow for rational choices within this important therapeutic class.
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